Skip to main content

Bilateral Nasal Polyposis

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Paratek Pharmaceuticals
1 program
1
OPN-375Phase 31 trial
Active Trials
NCT03747458Completed40Est. Jun 2026
Idorsia
IdorsiaSwitzerland - Allschwil
1 program
1
ACT-774312Phase 21 trial
Active Trials
NCT03688555Completed10Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Paratek PharmaceuticalsOPN-375
IdorsiaACT-774312

Clinical Trials (2)

Total enrollment: 50 patients across 2 trials

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Start: Dec 2018Est. completion: Jun 202640 patients
Phase 3Completed

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

Start: Oct 2018Est. completion: Dec 202010 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.